Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.

Description

uMotif is an innovative platform for eCOA/ePRO and eConsent, aimed at enhancing both clinical and real-world research efforts. Created with input from patients, this platform offers unmatched engagement, significantly improving the speed, quality, and precision of data collection. Through the integration of uMotif's eCOA/ePRO system with real-time glucose monitoring, the platform achieved remarkable compliance rates during a comprehensive diabetes study across Europe. In another instance, an immunology trial benefited from the patient-focused eCOA/ePRO solution, enabling the sponsor to fulfill data requirements a full six months ahead of schedule. Additionally, in a CNS study mandated by the FDA, participants utilized their personal devices to provide submission-ready ePRO data, showcasing the platform's versatility. uMotif's commitment to a patient-first design philosophy emphasizes a deep understanding of the patient experience and the factors influencing their behavior. This expertise not only ensures the development of software that addresses patient needs effectively but also results in extraordinarily high engagement levels for study sponsors, fostering a win-win environment for both parties.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Hillo

Country

France

Website

www.hillo.ai/

Vendor Details

Company Name

uMotif

Founded

2012

Country

United Kingdom

Website

umotif.com

Product Features

Product Features

Clinical Trial Management

21 CFR Part 11 Compliance
Document Management
Electronic Data Capture
Enrollment Management
HIPAA Compliant
Monitoring
Patient Database
Recruiting Management
Scheduling
Study Planning

Alternatives

Alternatives

Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs